Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335068 | 0.82 | AOC3 (0.40) | OPRK1TSHRACHEBCHEFAAH | |
| SCHEMBL334403 | 0.81 | AOC3 (0.41) | OPRK1SLC6A2SLC6A4 | |
| SCHEMBL335051 | 0.81 | AOC3 (0.41) | OPRK1SLC6A2SLC6A4 | |
| SCHEMBL1132949 | 0.81 | OPRK1 (0.53) | OPRK1TSHRALDH1A1ACHECYP3A4 | |
| Hydrochloric Acid SCHEMBL30606596 | 0.79 | AOC3 (0.40) | OPRK1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL26598980 | 0.79 | AOC3 (0.40) | OPRK1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL26598981 | 0.79 | AOC3 (0.40) | OPRK1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL31500336 | 0.79 | AOC3 (0.40) | OPRK1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL26598986 | 0.79 | AOC3 (0.40) | OPRK1SLC6A2SLC6A4 | |
| SCHEMBL335260 | 0.79 | HRH1 (0.45) | TSHRSLC6A4CYP3A4CYP2D6SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | GBA1 530/4885OPRK1 4818/4885TSHR 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.